JASON ERIKSEN to Humans
This is a "connection" page, showing publications JASON ERIKSEN has written about Humans.
Connection Strength
0.101
-
The enigmatic roles of microglial versus neuronal progranulin in neurological disease. Acta Neuropathol. 2010 Jan; 119(1):107-9.
Score: 0.009
-
Biologic models of neurodegenerative disorders. Handb Clin Neurol. 2008; 89:173-88.
Score: 0.007
-
Progranulin: normal function and role in neurodegeneration. J Neurochem. 2008 Jan; 104(2):287-97.
Score: 0.007
-
Plaques, tangles, and memory loss in mouse models of neurodegeneration. Behav Genet. 2007 Jan; 37(1):79-100.
Score: 0.007
-
Gene dosage and pathogenesis of Parkinson's disease. Trends Mol Med. 2005 Mar; 11(3):91-6.
Score: 0.006
-
Molecular pathogenesis of Parkinson disease. Arch Neurol. 2005 Mar; 62(3):353-7.
Score: 0.006
-
Caught in the act: alpha-synuclein is the culprit in Parkinson's disease. Neuron. 2003 Oct 30; 40(3):453-6.
Score: 0.006
-
NSAIDs and enantiomers of flurbiprofen target gamma-secretase and lower Abeta 42 in vivo. J Clin Invest. 2003 Aug; 112(3):440-9.
Score: 0.006
-
1-Indanone and 1,3-indandione Derivatives as Ligands for Misfolded a-Synuclein Aggregates. ChemMedChem. 2022 01 19; 17(2):e202100611.
Score: 0.005
-
One-Step Transformation from Rofecoxib to a COX-2 NIR Probe for Human Cancer Tissue/Organoid Targeted Bioimaging. ACS Appl Bio Mater. 2021 03 15; 4(3):2723-2731.
Score: 0.005
-
Cycad Genotoxin Methylazoxymethanol Disrupts the Brain Ubiquitin-Proteasome Pathway, Tau and a-Synuclein, as Reported in ALS-PDC. J Neuropathol Exp Neurol. 2021 02 22; 80(3):286-288.
Score: 0.005
-
Three-Dimensional Microscopy by Milling with Ultraviolet Excitation. Sci Rep. 2019 10 10; 9(1):14578.
Score: 0.004
-
7B2 chaperone knockout in APP model mice results in reduced plaque burden. Sci Rep. 2018 06 28; 8(1):9813.
Score: 0.004
-
Guidelines for the use and interpretation of assays for monitoring autophagy (3rd edition). Autophagy. 2016; 12(1):1-222.
Score: 0.003
-
A novel function for proSAAS as an amyloid anti-aggregant in Alzheimer's disease. J Neurochem. 2014 Feb; 128(3):419-30.
Score: 0.003
-
The neuroendocrine protein 7B2 suppresses the aggregation of neurodegenerative disease-related proteins. J Biol Chem. 2013 Jan 11; 288(2):1114-24.
Score: 0.003
-
Common variation in the miR-659 binding-site of GRN is a major risk factor for TDP43-positive frontotemporal dementia. Hum Mol Genet. 2008 Dec 01; 17(23):3631-42.
Score: 0.002
-
Substrate-targeting gamma-secretase modulators. Nature. 2008 Jun 12; 453(7197):925-9.
Score: 0.002
-
NSAIDs: small molecules for prevention of Alzheimer's disease or precursors for future drug development? Trends Pharmacol Sci. 2007 Oct; 28(10):536-43.
Score: 0.002
-
Mutations in progranulin cause tau-negative frontotemporal dementia linked to chromosome 17. Nature. 2006 Aug 24; 442(7105):916-9.
Score: 0.002
-
A decade of modeling Alzheimer's disease in transgenic mice. Trends Genet. 2006 May; 22(5):281-9.
Score: 0.002
-
Abeta42 is essential for parenchymal and vascular amyloid deposition in mice. Neuron. 2005 Jul 21; 47(2):191-199.
Score: 0.002
-
Diverse compounds mimic Alzheimer disease-causing mutations by augmenting Abeta42 production. Nat Med. 2005 May; 11(5):545-50.
Score: 0.002
-
Development of a high throughput drug screening assay for the detection of changes in tau levels -- proof of concept with HSP90 inhibitors. Curr Alzheimer Res. 2005 Apr; 2(2):231-8.
Score: 0.002
-
Abeta42-lowering nonsteroidal anti-inflammatory drugs preserve intramembrane cleavage of the amyloid precursor protein (APP) and ErbB-4 receptor and signaling through the APP intracellular domain. J Biol Chem. 2003 Aug 15; 278(33):30748-54.
Score: 0.001
-
A subset of NSAIDs lower amyloidogenic Abeta42 independently of cyclooxygenase activity. Nature. 2001 Nov 08; 414(6860):212-6.
Score: 0.001